CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 214 enrolled
Drug / intervention
Metronidazole (male partner) +1 moredrug
Likely dose
Metronidazole (male partner) 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02209519
NCT02209519Phase 3Completed
CompareCT.gov

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

University of Alabama at Birmingham·interventional·Posted Aug 6, 2014·Updated Apr 27, 2020

In Brief

A Phase 3 clinical trial evaluating Metronidazole (male partner) and Placeob (male partner) for Recurrent Bacterial Vaginosis. Completed, enrolled 214 participants across 1 site.

Detailed Summary

Male partners of womoen with recurrent bacteria vaginosis are randomized to treatment with metronidazole or placebo to compare the rates of recurrent BV in the women

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Bacterial Vaginosis
CountriesUnited States
CollaboratorsWayne State University

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 6, 2014
Enrollment StartFeb 1, 2015
Primary CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.9 years ago

Interventions

Metronidazole (male partner)drug

500 mg PO BID for 7 days

Placeob (male partner)other

matching placebo capsules PO BID for 7 days